FDA Inspection 1048077 — Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. — FEI 3011431238

The FDA completed an inspection of Sarepta Therapeutics, Inc. on April 12, 2018 in Cambridge, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 12, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Cambridge, MA (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
1802421 CFR 314.80(c)(2)(ii)(B)Periodic safety report missing ICSR